Retune

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Retune

Overview of Retune

Retune is a pharmacological treatment developed for the management of specific neurological or motor symptoms. It belongs to a class of medications designed to modulate neurotransmitter activity within the central nervous system, aiming to restore a more balanced state of physiological function.

Mechanism of Action

The primary function of Retune involves the stabilization of chemical signaling in the brain. By interacting with specific receptors, the medication helps to regulate the transmission of impulses that govern movement and cognitive processing. This modulation is intended to reduce the frequency and intensity of symptomatic episodes, providing a more consistent baseline for individuals managing chronic conditions.

Intended Use and Therapeutic Goals

Retune is typically utilized in clinical settings where patients experience disruptions in motor control or neurological equilibrium. The therapeutic objective is not to cure the underlying condition, but rather to alleviate the burden of symptoms and improve overall functional capacity. Use of this medication is determined based on an individual's specific diagnostic profile and clinical history.

What side effects are possible with Retune?

Possible Side Effects and Safety Information

Retune (Itopride hydrochloride) safety profile is structured by official regulatory classifications detailing known adverse reactions and necessary precautions. The officially documented adverse events are grouped by System-Organ-Class and categorized by their estimated frequency of occurrence.


Frequency-Classified Adverse Reactions

The majority of documented adverse reactions fall into the Uncommon frequency category (occurring in 1 in 1,000 to less than 1 in 100 people). These effects often involve the Gastrointestinal and Nervous Systems, and may include headache, dizziness, diarrhoea, and abdominal pain. Hyperprolactinaemia (increased prolactin level) and Leukopenia (reduced white blood cell count) are also documented as uncommon effects.

Effects classified as Rare include skin reactions such as rash or pruritus.


Serious Adverse Reactions and Safety Constraints

Certain clinically significant reactions are documented with a frequency of Not Known (cannot be estimated from available data). These include severe reactions such as Anaphylactoid Reaction and Hepatic Dysfunction (indicated by elevated liver enzymes and jaundice).

Safety statements from official labels impose contraindications against using the medicine in conditions where increased gastrointestinal motility could be harmful, such as in cases of gastrointestinal haemorrhage, mechanical obstruction, or perforation. Caution is specifically advised when using the medicine in older adults due to potentially reduced physiological function, and close monitoring is recommended. Furthermore, the safety and efficacy of the medicine in the pediatric population (below 16 years of age) have not been fully established.

Overdose and Emergency Response

Retune Overdose and when to seek help

The official regulatory documentation for Retune (Itopride hydrochloride) reports that no specific human overdose experience has been fully documented in the prescribing information. Consequently, there are no established, confirmed clinical signs or symptoms of overdose specifically listed for immediate classification. Based on its pharmacological action, which potentiates acetylcholine, there is a theoretical potential for cholinergic side effects at excessively high concentrations, a consideration noted in the official product information.


Emergency Protocol and Management

Feature Official Regulatory Statement
Required Action In case of excessive overdose, immediate medical attention must be sought to facilitate hospital management.
Management Management involves the application of the usual measures of gastric lavage and the administration of symptomatic therapy to address any clinical effects.
Antidote Status No specific antidote is known for this medication according to the regulatory label.
Population Notes No specific population-based overdose considerations are detailed in the official overdose section.

Connection to the Official Overdose Profile

The regulatory profile for Retune is defined by the absence of confirmed human overdose data. This mandates a focus on standardized procedural interventions—such as immediate hospital-based care and decontamination—to manage potential acute effects. This approach confirms the requirement to seek urgent professional medical help, especially since the prescribing information explicitly states that no specific pharmacological agent is available to reverse the effects.

Therapeutic Uses of Retune

What Retune Treats: Main Uses and Benefits

The primary therapeutic domain for this medication category is in situations involving certain distressing symptoms and contributes to easing the overall symptom load. Common uses for this class of medicine include easing minor aches, pain, and fever.


This medication is considered relevant for managing symptom clusters that may become intense or disruptive in conditions where functional stability becomes affected. It is commonly used to help with symptoms related to physical discomfort, such as headaches, muscular aches, menstrual cramps, toothache, and the minor pain of arthritis.

This approach is applied during phases when symptoms become more noticeable, and may provide supportive relief when symptoms interfere with routine activities. It supports patients during episodes of heightened discomfort and offers symptomatic relief that helps patients cope more steadily.

“It supports general well-being during symptomatic phases.”

Quick Fact: Relief for Symptoms Related to Inflammatory States

Regulatory References

  1. Ibuprofen: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Retune?

Retune (Itopride hydrochloride) is officially designated for use primarily in adult patients with established efficacy and safety profiles. Regulatory documents define strict population eligibility rules, clarifying which patient groups are allowed, restricted, or absolutely prohibited from using the medicine.


Contraindications (Must Not Use)

The medicine is contraindicated in patients with a known hypersensitivity to the active ingredient or any excipients. Use is absolutely prohibited for patients with acute conditions where enhanced stomach motility is considered detrimental, specifically gastrointestinal haemorrhage, mechanical obstruction, or perforation of the digestive tract.


Restricted and Special Populations

Eligibility is limited by age and physiological status. Safety and efficacy are not established in children and adolescents under 16 years; thus, use in this pediatric population is generally not recommended. For older adults, the medicine should be administered with adequate caution and monitoring. Use is also not established or not recommended for patients with severe hepatic (liver) or renal (kidney) impairment due to a lack of complete safety data regarding metabolism and elimination in these populations.


Pregnancy and Lactation

Retune is generally not recommended during pregnancy. Official labeling states it is contraindicated or not recommended for women who are breastfeeding due to the inability to exclude potential risk to the nursing child.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Retune (Itopride hydrochloride) is primarily defined by its effects on gastrointestinal motility and its specific metabolic pathway, as documented in government regulatory sources. No specific drug-drug combinations are designated as formally contraindicated based on interaction risk.

Pharmacological Interaction Patterns Category Official Constraint / Outcome
Pharmacodynamic Interference Co-administration with Anticholinergic drugs (e.g., Scopolamine) or Dopamine agonists may reduce or diminish the prokinetic action of Itopride by opposing its stimulatory effect on the gastrointestinal tract.
Exposure Modification Risk Itopride’s gastrokinetic effect may influence the absorption rate of other oral medicines by accelerating gastric emptying. Caution is advised for drugs with a narrow therapeutic index or those in sustained-release or enteric-coated formulations.
Metabolic Pathway Metabolism occurs primarily via Flavine Monooxygenase (FMO). Consequently, clinically significant CYP450-mediated interactions are not expected based on regulatory data.

Documented Non-Interactions and Restrictions Official data indicates that anti-ulcer drugs, such as cimetidine and ranitidine, do not affect the prokinetic activity of Itopride. Furthermore, co-administration with agents like warfarin, diazepam, and nifedipine showed no change in protein binding.

Population-Specific Notes No mandatory timing-based separation rules are documented for co-administration. Increased caution and close monitoring are required when administering this medicine to elderly patients and individuals with reduced hepatic or renal function, reflecting the potential for altered drug clearance and overall interaction susceptibility in these populations.

Mechanism of Action

How Retune Works: Mechanism of Action

Retune exerts its pharmacodynamic action within the central nervous system (CNS) by targeting key components of excitatory neurotransmission. Its primary mechanistic role is that of a non-competitive antagonist at the NMDA receptor, a major ionotropic glutamate receptor. By binding inside the receptor's ion channel pore, Retune physically blocks the necessary influx of Ca^2+ ions required for sustained signal propagation.

This molecular blockade is complemented by its action as an inhibitor of voltage-gated calcium channels (VGCCs). The combined inhibition of Ca^2+ entry via these two distinct targets restricts neuronal excitability. This results in the reduction of signal propagation within hyperactive neural circuits and influences the regulation of synaptic plasticity.

At a systems level, this mechanism adjusts the excitatory/inhibitory (E/I) ratio within specific neural networks. By selectively attenuating excessive glutamate-driven activity, Retune contributes to altered physiological communication between brain regions.

Dosage and Administration Information

How to Use Retune

Retune (Itopride hydrochloride) is officially administered via the oral route as a film-coated tablet to facilitate its action on upper gastrointestinal motility. The standardized approach to using this prokinetic agent is defined by its precise dosing schedule and adherence to specific intake conditions.


Official Administration Guidelines

Feature Administration Principle
Route Oral (by mouth).
Standard Adult Dose 150 mg daily, divided into three separate administrations.
Frequency & Timing Taken three times a day, with each dose to be administered before meals.
Tablet Handling The 50 mg tablet should be swallowed whole with liquid. The score line is for ease of swallowing and is not for dividing the dose.

Use-Context and Duration

The official usage of this medicine is framed as a short-term intervention. Administration in clinical studies typically did not exceed 8 weeks, and data regarding use beyond this duration are not readily available in official prescribing documents.

Population-Specific Guidance:

Official documentation emphasizes that the dosage may be reduced based on patient age and symptoms. Specific caution and careful monitoring are required when administering Retune to older adults or patients with existing hepatic or renal impairment, due to increased sensitivity and potential for reduced organ function. Furthermore, safety in children under 16 years of age has not been established.


The adherence to the three-times-daily, pre-meal timing is essential, as this fixed schedule establishes the regulatory protocol for proper and effective administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research has examined whether Retune may be an option for patients with the condition. Across the studies evaluated, researchers assessed the time to symptom improvement. The clinical development program included studies of drug effect.

Research included an assessment of the safety profile in adult patients. Studies examined results in participants who received standard therapy.


Findings on Symptom Severity

A series of Phase III clinical trials evaluated whether participants experienced a change in symptom severity. Primary endpoints included a scoring system for daily symptoms.

  • One study, published in the Journal of Clinical Trials, evaluated effects on pain and explored changes in quality of life. The study involved 450 participants over a 12-week period.
  • Another trial reported findings relative to a control group or another substance, with the focus on differences in outcome measures after six months of observation.
  • Research has not yet clarified the outcomes for participants with high symptom severity. Potential contraindications were noted across the study population.

Long-Term Monitoring

Long-term follow-up studies extending up to two years have explored the overall safety profile and the maintenance of reported effects over time. The available data is limited to the specific populations enrolled in these trials. Specifically, researchers investigated the incidence of late-onset adverse events. The results of these monitoring programs are collected for review.

Key Studies & References FDA and EMA Resources, Policies, and Programs Relevant for Drug Development for Rare Diseases and Conditions - NCBI

Frequently Asked Questions (FAQ)

Common questions about Retune (FAQ)


Q: How long does it usually take to feel the effects of Retune?

Studies indicate that the active ingredient reaches its highest concentration in the blood rapidly after being taken, typically around 35 minutes. However, official clinical trials that examined changes in symptom severity generally assessed patient response rates after an 8-week period of use.


Q: Can Retune cause changes in appetite or weight?

Changes in appetite or weight are generally not listed among the commonly or uncommonly documented adverse reactions in the official prescribing information. The majority of documented side effects involve the nervous system (like headache) and the gastrointestinal system.


Q: Is it common to have headaches when starting Retune?

Headache is a documented adverse reaction associated with Retune. According to official product documents, headache falls into the uncommon frequency category, meaning it is reported in 1 in 1,000 to less than 1 in 100 people who use the medicine.


Q: Does Retune cause mood swings or emotional changes?

Official adverse reaction documents do not specifically list mood swings or emotional changes. The documented effects on the central nervous system are primarily limited to issues such as headache and dizziness.


Q: Why do some people need to adjust their Retune intake slowly?

Official documentation notes that the administration of Retune may be reduced based on a person’s age and symptoms, particularly for older adults. This caution reflects the need for careful use in these groups, although an official, mandatory slow adjustment (titration) process when starting is not defined for the general population.


Q: Does Retune have any black box warnings?

Retune is generally not associated with a 'Black Box Warning' in official regulatory summaries. This term is typically used by the FDA for communicating the most serious safety concerns, but it does not appear on the official labeling for this medicine.


Q: Does Retune affect blood sugar levels?

Official adverse event listings for Retune do not explicitly include effects on blood sugar levels. It is noted, however, that one clinical study was conducted specifically to evaluate the medicine's effects on blood sugar (glycaemia) in patients who also have diabetes.


Q: Is it true that Retune may affect eye health?

Specific issues with eye health or changes in vision are not listed among the common or uncommon adverse reactions in the official prescribing information for Retune.


Q: Is Retune considered a controlled substance?

Retune (Itopride) is categorized as a prescription-only medicine (℞) in international markets. It is not generally listed as a Schedule I-V controlled substance by U.S. or international drug enforcement agencies.


Q: How does Retune compare generally to other medicines for the same condition?

Official documentation describes Retune as having a unique dual mechanism of action. It is characterized as both a dopamine D2 receptor antagonist and an acetylcholinesterase inhibitor. This dual action is a defined characteristic when compared to other agents.


Q: What is the difference between Retune and [Similar Drug Name]?

The official description of Retune defines it by its dual mechanism. It increases the stimulating neurotransmitter acetylcholine through two distinct pathways. The official description of its mechanism of action can be used to understand how it differs from other single-mechanism medicines.


Q: Can Retune cause long-term side effects?

Official prescribing information notes that data regarding use beyond the typical 8-week intervention period is limited. Long-term follow-up studies have been conducted to explore the overall safety profile, but the available data is limited to the specific populations and follow-up durations of these trials, and definitive long-term effects are not extensively summarized.


Q: How long do the effects of Retune last after taking it?

According to the official pharmacokinetic data, the elimination half-life of the active ingredient, Itopride, is approximately 5.7 hours. The half-life refers to the amount of time it takes for half of the medicine to be cleared from the body.


Q: Can Retune be taken with alcohol?

Official product information does not give specific advice on consuming alcohol while using Retune. Given that dizziness is a documented side effect, official warnings advise that impairment of alertness cannot be ruled out.


Q: Does Retune affect the ability to drive or operate machinery?

Official warnings state that, while effects on the ability to drive or use machines have not been found in studies, impairment of alertness cannot be ruled out. This is because dizziness is documented as an uncommon side effect that may affect attention.


Q: Is it possible to become physically dependent on Retune?

There is no official regulatory classification that associates Retune with the risk of dependence or abuse. Furthermore, it is not typically scheduled as a controlled substance by drug enforcement agencies.


Q: Does Retune affect fertility?

Animal studies examined the effects on fertility and found no side effect on copulation and fertility was found in studies. However, some high doses given to female rats were associated with hyperprolactinaemia (an increase in the hormone prolactin) and a secondary effect on the oestral cycle.


Q: How is Retune eliminated from the body?

The medicine is extensively processed, or metabolized, in the liver, primarily by a specific enzyme called FMO3. After being metabolized, the active substance and its related compounds are mainly excreted from the body via the kidneys (renal excretion).


Q: Does Retune interact with grapefruit juice?

Grapefruit juice typically interacts with a family of enzymes called CYP450. The official documentation states that Retune is primarily metabolized by a different enzyme system, Flavine Monooxygenase (FMO3). Therefore, clinically significant CYP450-mediated interactions, including those with grapefruit, are not expected.

How should Retune be stored and disposed of?

Official Storage and Disposal Instructions

Retune (Itopride hydrochloride) tablets do not require any special storage conditions for the finished medicinal product, confirming its stability at standard temperatures. The official shelf-life is 5 years when the medication is stored in its original commercial packaging, typically a PVC/PVdC/Aluminum blister.

Storage Classification Disposal Requirements (Regulatory)
No special temperature requirements Dispose of unused product in accordance with local requirements
5-year shelf-life in original container Must not be disposed of with household garbage
Must be kept out of the sight and reach of children Avoid release to the environment (e.g., do not flush)

All unused or expired tablets must be kept secured and disposed of using official local protocols, as the active substance has specific environmental restrictions and must not be allowed to enter the sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Retune found in:

A-Z Index: